BlackRock
TLIS

BlackRock’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

BlackRock’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,271
Closed -$37K – 5366
2024
Q2 		$37K Sell
4,271
-440
-9% -$3.9K ﹤0.01% 4915
2024
Q1 		$41.2K Sell
4,711
-5,721
-55% -$47.2K ﹤0.01% 4913
2023
Q4 		$77.7K Buy
10,432
+5,506
+112% +$35.9K ﹤0.01% 4874
2023
Q3 		$28.4K Sell
4,926
-161
-3% -$1.1K ﹤0.01% 5093
2023
Q2 		$36.6K Sell
5,087
-411
-7% -$2.98K ﹤0.01% 5120
2023
Q1 		$40.4K Sell
5,498
-966
-15% -$8.21K ﹤0.01% 5157
2022
Q4 		$43.2K Sell
6,464
-17
-0.3% -$149 ﹤0.01% 5261
2022
Q3 		$65K Sell
6,481
-357
-5% -$4.51K ﹤0.01% 5301
2022
Q2 		$84K Sell
6,838
-47,895
-88% -$757K ﹤0.01% 5284
2022
Q1 		$1.16M Buy
54,733
+331
+0.6% +$11.5K ﹤0.01% 4618
2021
Q4 		$3.27M Buy
54,402
+193
+0.4% +$14.4K ﹤0.01% 4191
2021
Q3 		$5.08M Buy
54,209
+389
+0.7% +$51.8K ﹤0.01% 3951
2021
Q2 		$8.9M Buy
53,820
+5,660
+12% +$961K ﹤0.01% 3679
2021
Q1 		$9.28M Buy
+48,160
New +$12M ﹤0.01% 3616

Other funds holding TLIS

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

BlackRock's TLIS Position: Q3 2024 in Review

BlackRock sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2024, closing a stake of 4,271 shares — an estimated $37K sold.

BlackRock first reported a position in TLIS in Q1 2021 and held it in 14 quarters. The position peaked at $9.28M in Q1 2021. 2 funds tracked by Wall St. Rank hold TLIS as of Q3 2024.

  • BlackRock reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2024 after selling out during the quarter.
  • BlackRock sold 4,271 Talis Biomedical Corporation Common Stock shares in Q3 2024, an estimated $37K.
  • BlackRock first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 14 quarters.
  • BlackRock's Talis Biomedical Corporation Common Stock position peaked at $9.28M in Q1 2021.
  • 2 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2024.

Based on BlackRock's 13F filing for Q3 2024, filed 13 Nov 2024.